Circulating Adenosine Levels Before and After IV Persantine

This study is currently recruiting participants.

Verified by University of Connecticut, March 2009

First Received: September 24, 2008 Last Updated: March 19, 2009 History of Changes

Sponsors and Collaborators:	University of Connecticut Health Center U.S. Army Research, Department of Defense
Information provided by:	University of Connecticut
ClinicalTrials.gov Identifier:	NCT00760708

Purpose

Persantine is a drug that is routinely used to determine blood flow to the heart in the diagnosis of coronary heart disease. Persantine causes an increase in the adenosine level in the blood. Adenosine is a naturally occuring substance in the body that can increase blood flow. Adenosine is normally removed from the bloodstream by an adenosine transporter, which is a protein that takes up adenosine from the blood into cells. The increase in adenosine levels in the blood is variable, and the cause for this variability is unknown. A mutation for this transporter gene may contribute to this variability, and may alter its function. Thus, the purpose of this study is to determine the relationship between the mutation and the transporter function.

Condition
Ischemia Coronary Disease

MedlinePlus related topics: Coronary Artery Disease

Drug Information available for: Dipyridamole Adenosine

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case Control, Prospective
Official Title:	Circulating Adenosine Levels Before and After IV Persantine

Further study details as provided by University of Connecticut:

Primary Outcome Measures:

To determine functional significance and association of these polymorphisms with the ability of persantine to inhibit uridine (uridine uses the same transporter) uptake and platelet aggregation. [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

We will also study the association of these polymorphisms with any clinical characteristics such as the incidence of MI, acute coronary syndrome, coronary bypass or stenting procedures. These clinical outcomes are considered secondary endpoints. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Biospecimen Retention: Samples With DNA

Biospecimen Description:

whole blood

Estimated Enrollment:	110
Study Start Date:	September 2005
Estimated Study Completion Date:	September 2011
Estimated Primary Completion Date:	September 2011 (Final data collection date for primary outcome measure)

Groups/Cohorts
undergoing persantine stress test

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

Subjects undergoing a Persantine nuclear stress test.

Criteria

Inclusion Criteria:

Subjects with or without coronary artery disease undergoing a Persantine nuclear stress test

Exclusion Criteria:

Oral persantine use within 24 hours
Second or third degree AV block, or sick sinus syndrome without a functioning pacemaker
Active asthma or bronchospasm
Those with end-stage liver disease such as cirrhosis or active hepatitis such as > 5 fold liver enzyme elevation will not be included
Anemia (Hct < 30)
Myocardial infarction within 30 days
Severe left ventricular dysfunction (EF < 30%)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00760708

Contacts

Contact: Jayne M Schumacher, BS,RN

860-679-2692

schumacher@uchc.edu

Locations

United States, Connecticut
University of Connecticut Health Center	Recruiting
Farmington, Connecticut, United States, 06030

Sponsors and Collaborators

University of Connecticut Health Center

U.S. Army Research, Department of Defense

Investigators

Principal Investigator:

Bruce T Liang, MD

University of Connecticut Health Center

More Information

No publications provided

Responsible Party:	University of Connecticut Health Center ( Bruce T. Liang, MD/ Professor and Chief of Cardiology )
Study ID Numbers:	02-115-1, Proposal Number 04156012, Award NumberW81XWH-05-1-0060
Study First Received:	September 24, 2008
Last Updated:	March 19, 2009
ClinicalTrials.gov Identifier:	NCT00760708 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Connecticut:

nucleosides
neurotransmitter
myocardial ischemia
Adenosine

Study placed in the following topic categories:

Arterial Occlusive Diseases
Vasodilator Agents
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Cardiovascular Agents
Ischemia
Arteriosclerosis
Coronary Disease

Phosphodiesterase Inhibitors
Platelet Aggregation Inhibitors
Analgesics
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Dipyridamole
Adenosine
Coronary Artery Disease

Additional relevant MeSH terms:

Vasodilator Agents
Molecular Mechanisms of Pharmacological Action
Myocardial Ischemia
Hematologic Agents
Physiological Effects of Drugs
Arteriosclerosis
Pathologic Processes
Sensory System Agents
Therapeutic Uses
Cardiovascular Diseases
Analgesics
Anti-Arrhythmia Agents
Arterial Occlusive Diseases
Heart Diseases

Vascular Diseases
Enzyme Inhibitors
Ischemia
Cardiovascular Agents
Pharmacologic Actions
Coronary Disease
Phosphodiesterase Inhibitors
Platelet Aggregation Inhibitors
Peripheral Nervous System Agents
Dipyridamole
Adenosine
Central Nervous System Agents
Coronary Artery Disease

ClinicalTrials.gov processed this record on May 07, 2009